Biography
Before joining CSCI, Dr Konstantinos Tzelepis was a group leader at the The Milner Therapeutics Institute, University of Cambridge (UK). Prior to this, he was a Wellcome Trust Sir Henry Wellcome Fellow at Harvard University (USA) and the University of Cambridge (UK). Konstantinos graduated from the University of West Attica (Greece) with a B.S. in Biomedical Sciences in 2009 and then from the Medical School of the National and Kapodistrian University of Athens (Greece) with a M.S. in Cancer Biology in 2010. Konstantinos obtained his Ph.D. in Molecular Genetics from the Wellcome Sanger Institute and the University of Cambridge, in 2017, working on developing one of the first genome-wide CRISPR screening platforms for the identification of cancer vulnerabilities and novel therapeutic targets.
Publications
- Yankova, Blackaby et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021
- Orellana et al. METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell 2021
- Mikutis et al. meCLICK-Seq – a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. ACS Central Science 2020
